We’re re-posting this important announcement from Staff News. Earlier this year new federal regulations went into effect related to equal opportunity and affirmative action requirements for federal contractors, such as OHSU. Part of these new regulations requires OHSU to give all current employees the opportunity to voluntarily self-identify veteran status and disability status. To meet these requirements, OHSU is beginning a new compliance process known as Personal Information Verification, which all employees are required to … Read More
When a company looks at bringing in a new technology to commercialize, they perform due diligence on a wide array of different topics to allay the potential risks. What are these risks and what kind of questions do they ask? What kind of information can we provide to maximize interest and licensing revenue? In this presentation, TTBD Technology Development Managers, Rob Copenhaver and Trina Voss, will discuss the questions companies ask when evaluating a licensing … Read More
Please join us for a special biostatistics presentation, featuring David Yanez, Ph.D., an associate professor in the Department of Biostatistics at University of Washington. Dr. Yanez has been involved in a wide variety of collaborative clinical and translational research. His statistical methodology interests include analysis of overdispersed data, joint modeling of mean and dispersion parameters and quasi-likelihood models, as well as his current interest in models for measurement error. He will present recent work in this latter … Read More
OCTRI’s Clinical and Translational Research Center and Epilepsy Monitoring Unit has recently undergone construction to provide first class care and research capabilities. Supported by heightened staffing, space and state-of-the-art equipment, this new unit will strengthen and elevate the care of patients with neurologic diseases and support clinical research across a broad spectrum. Please join us for an open house to learn more about the facility, tour and enjoy refreshments. Clinical and Translational Research Center and … Read More
Few things are as frustrating as writing a great grant that is not funded because the funding percentile is so low–and then having to figure out how to drastically revise it to meet the requirement of writing a “new” application. Effective now, that pain point is going away: As of April 17, 2014, the NIH and AHRQ no longer require new (A0) grant applications to demonstrate significant changes in scientific direction, even if the project was … Read More
The $125 million gift from Nike co-founder and Chairman Phil Knight and his wife Penny that formed the OHSU Knight Cardiovascular Institute has rallied researchers around the developmental origins of cardiovascular disease. This gift has already inspired many changes as the institute works to become a leader in translational cardiovascular research. One major change is the transition of the Heart Research Center into the newly formed Center for Developmental Health to reflect a focus on … Read More
Check out the Technology Transfer & Business Development 2014 first quarter Newsletter. In this issue, we discuss: Business Development Updates – Hear about the Business Development Research Consortia and how our second annual Startup Symposium was a great success United States Legislation Update – Keep up-to-date on “the Innovation Act” and “the Transfer Act of 2013” and how it might affect you TTBD Patent Evaluation Process – Learn more about our patent evaluation process along with the requirements to … Read More
As of 12 p.m. on Friday, Dec. 5, FedEx has informed OHSU that they will be picking up early today due to the weather. This will cause the shipping department to discontinue services at 2 p.m. this afternoon. If you have an urgent package that needs to be shipped today, check with the shipping office at ext. 4-7380. Please visit the Staff News blog for continued winter weather updates.
The New York Times December 2 “Science” section featured the work of Lynn Sakai, Ph.D., Senior Investigator at the Portland Shriners Research Center and Professor of Biochemistry & Molecular Biology, OHSU. Dr. Sakai and her colleagues have been studying the use of fibrillin-1 levels–the protein associated with Marfan syndrome–as a blood test for aortic ruptures. Read the Times feature here.
The OHSU Gene Therapy Working Group and the Rare Disorders Research Consortium invite you to attend the 2nd Annual Gene Therapy Symposium, an afternoon event to showcase OHSU’s Gene Therapy research excellence. “Gene Therapy at OHSU” Thursday, November 21, 2013 2 to 6:30 p.m. The Joseph Vey Conference Center Featuring “Genes and Non Coding RNAs as Therapeutics” by keynote speaker Mark A. Kay, M.D., Ph.D., Dennis Farrey Family Professor, Departments of Pediatrics and Medical Genetics, Stanford … Read More